JERSEY CITY, N.J.--(BUSINESS WIRE)--ACAAI- new pooled post-hoc analysis of VTAMA (tapinarof) cream, 1% demonstrates consistent response for atopic dermatitis disease severity and itch.
Organon and Co. (NYSE: OGN - Get Free Report) and CASI Pharmaceuticals (NASDAQ: CASI - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Earnings and Valuation This table compares Organon
Organon (OGN) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $1.01 per share a year ago.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the third quarter 2026, which will be.
Organon and Co. (NYSE: OGN - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Institutional and Insider Ownership 77.4% of Organon
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.